July 20, 2005 14:46 ET

New Coverage of Nymox Initiated by Cohen Independent Research Group

MAYWOOD, N.J.--(CCNMatthews - Jul 20, 2005) -

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that Cohen Independent Research Group has initiated research coverage of the Company. The report is available at www.cohenresearch.com as well as from First Call, Bloomberg, and other leading providers.

The base case assumption of the report values NYMX at $9.30 per share with a target of $7.20. The report states, "We believe the stock is well suited for investors seeking long term growth."

Cohen Independent Research Group (CIRG) is considered by many to be Wall Street's top independent research firm. CIRG distributes and provides research and analyst coverage for selected companies with outstanding business models. CIRG has issued a 105 page research report on NYMOX. The report can be accessed on CIRG's website: www.cohenresearch.com.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    website: www.nymox.com